11 withdrawn. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Withdrawn 11 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ketamine Biomarker Validation Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg) - Treatment Resistant Depression (TRD) | Phase 1 | Withdrawn | Soterix Medical | 2025-12-20 | 2026-10-19 | |
| Enhancing Processing Speed and Executive Functioning in Depressed Older Adults With Computerized Cognitive Training Experimental: Computerized Cognitive Training, Experimental: Open-label antidepressant treatment, Active Comparator: Solitaire Training - Depression in Old Age, Depression | Phase 1 | Withdrawn | Queens College, The City University of New York | 2023-01-31 | 2023-03-28 | |
| A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression Esketamine, Cognitive Behavioral Therapy (CBT), Antidepressant - Depression | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2022-09-01 | 2025-04-27 | |
| A Study of SDI-118 in Participants in Remission From Depression SDI-118, Placebo - Depression in Remission | Phase 1 | Withdrawn | Syndesi Therapeutics | 2021-09-16 | 2022-04-22 | |
| Intravenous Ketamine Effects on Functional Neuroanatomy Ketamine - Depression | Phase 1 | Withdrawn | Neurological Associates of West Los Angeles | 2020-05-02 | 2020-06-01 | |
| Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression botulinum toxin A, Placebos - Major Depressive Disorder, Major Depressive Episode | Phase 1 | Withdrawn | Helse Stavanger HF | 2019-05-01 | 2021-08-11 | |
| Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men Mobile Phone Application - Depressive Symptoms, Anxiety Generalized | Phase 1 / Phase 2 | Withdrawn | Northwestern University | 2017-08-14 | 2017-08-17 | |
| Efficacy of TDCS for Treating Working Memory Dysfunction and Depression in Temporal Lobe Epilepsy Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation - Epilepsy | Phase 1 | Withdrawn | NYU Langone Health | 2012-11-01 | 2016-04-15 | |
| Brain Imaging, Genetics and Treatment for Major Depression Citalopram - Depressive Disorder, Depressive Disorder, Major | Phase 1 | Withdrawn | National Institute of Mental Health (NIMH) | 2012-03-12 | 2019-12-17 | |
| E-health Intervention for Cancer Survivors 2.0 Project Onward website + 16 person social network, Project Onward website + 8 person social network - Cancer | Phase 1 | Withdrawn | Northwestern University | 2011-05-01 | 2014-10-07 | |
| Primary Care iSBIRT to Reduce Serious Teen Health Risks iSBIRT, iSBIRT/TE - Substance-related Disorders, Depression | Phase 1 / Phase 2 | Withdrawn | Boston Children's Hospital | 2009-09-01 | 2016-10-07 |
Depression (11) · Depressive Disorder, Major (3) · Depressive Disorder, Treatment-Resistant (3) · Anxiety Disorders (2) · Depressive Disorder (2) · Alzheimer Disease (1) · Bisexuality (1) · Epilepsy (1) · Generalized Anxiety Disorder (1) · Homosexuality (1) · Marijuana Abuse (1) · Multiple Endocrine Neoplasia Type 1 (1) · Neoplasms (1) · Substance-Related Disorders (1) · Suicidal Ideation (1)
Behavior (11) · Mental Disorders (8) · Mood Disorders (5) · Depressive Disorder (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Nervous System Diseases (2) · Sexual Behavior (2) · Chemically-Induced Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dementia (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1)
Ketamine (2) · Antidepressive Agents (1) · Botulinum Toxins, Type A (1) · Citalopram (1) · Cognitive Behavioral Therapy (1) · Esketamine (1) · Sodium Chloride (1) · Transcranial Direct Current Stimulation (1)
Northwestern University (2) · Boston Children's Hospital (1) · Helse Stavanger HF (1) · Janssen Research & Development, LLC (1) · NYU Langone Health (1) · National Institute of Mental Health (NIMH) (1) · Neurological Associates of West Los Angeles (1) · Queens College, The City University of New York (1) · Soterix Medical (1) · Syndesi Therapeutics (1)
United States (8) · United Kingdom (1)
Anli Liu, MD (1) · David C. Mohr, Ph.D. (1) · Gonzalo Laje, M.D. (1) · Joel R Sneed, PhD (1) · John R Knight, MD (1) · Katharine Smith, DM (1) · Maeve Duffy, PhD (1) · Michelle N Burns, Ph.D. (1) · Sheldon Jordan, MD (1) · Taylor Kuhn, PhD (1)
K08MH094441 (1), R33MH126187 (1)